Brought to you by 
AOP gets European rights to Cardiome Pharma's Brinavess
22 Aug 2013
Executive Summary
AOP Orphan Pharmaceuticals AG has licensed certain European rights to Cardiome Pharma Corp.’s (cardiovascular drugs) Brinavess (vernakalant). The deal is for an initial three years, but is renewable annually thereafter.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AOP gets European rights to Cardiome Pharma's Brinavess
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice